{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1.58 vs. cons $1.51",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$4.40B vs. cons $4.36B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "NAST Adjusted Gross Margin %",
      "prediction": "MISS",
      "answer": "pred ~14.0% vs. cons/expectation ~14.6%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS guidance",
      "prediction": "LOWER",
      "answer": "guide ~$6.00 vs. cons $6.08 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Dry Van Spot Rate Assumption (cost headwind)",
      "prediction": "LOWER",
      "answer": "guide ~19% y/y vs. prior guide 17% y/y (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Litigation loss-contingency disclosure/reserve",
      "prediction": "UNKNOWN",
      "answer": "guide ~$0M booked (non-estimable) vs. street ballpark ~$150M potential exposure (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -4.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Even with a likely Q2 EPS/revenue beat, management reiterating the ~$6 FY26 EPS target (vs. $6.08-6.09 consensus) is an implicit downward revision that analysts will formalize over the following days; combined with NAST gross-margin compression from accelerating spot-rate cost inflation (17%\u2192~19% guided) and unresolved litigation/insurance-reserve overhang from the Dallas verdict, sell-side estimate cuts and target-price trims (already begun with Baird) should extend the initial negative reaction rather than let it fade, producing continued idiosyncratic underperformance through the week.",
  "day5_confidence": "MEDIUM"
}